Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

Marion Bennie, Brian Godman, Iain Bishop, Stephen Campbell

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Introduction: Multiple and intensive demand measures in Scotland have appreciably enhanced prescribing efficiency for proton pump inhibitors (PPIs) and statins in 2007 versus 2001. Statin utilization enhanced by measures to increase doses prescribed, including the Quality and Outcome Framework (QoF). Aims: Ascertain whether the plethora of measures continue to enhance prescribing efficiency for PPIs and statins. Second, assess whether the combined impact of the QoF targets and guidance enhances the prescribing of higher strength statins, mirroring the situation in England. Method: PPI and statin utilization measured in terms of defined daily doses (DDDs) and DDDs per 1000 inhabitants per day (2010 DDDs) between 2001 and 2010, number and strength of simvastatin and atorvastatin tablets dispensed, and reimbursed expenditure per DDD and 1000 inhabitants per year. Results: Expenditure per ODD for generic omeprazole in 2010 was 91% below the 2001 originator price, leading to expenditure per 1000 inhabitants for PPIs in 2010 to be 56% below 2001 despite a threefold increase in utilization. Expenditure per DDD for generic simvastatin in 2010 was 97% below the 2002 originator price. Expenditure per 1000 inhabitants for statins in 2010 only increased by 7% compared with 2001 despite a 6.2-fold increase in utilization. Utilization of higher strength statins has increased in recent years, with higher strength simvastatin (40 and 80 mg) accounting for 85% of total statins (DDD basis) in 2010. Conclusion: Reforms appear to be working to further enhance prescribing efficiency. Utilization of higher strength statins in recent years should further improve outcomes
Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalExpert Review of Pharmacoeconomics Outcomes Research
Volume12
Issue number1
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proton Pump Inhibitors
Scotland
Health Expenditures
Simvastatin
Omeprazole
England
Tablets

Cite this

@article{9a40b31eff144c0b87c05fe806dd1db9,
title = "Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland",
abstract = "Introduction: Multiple and intensive demand measures in Scotland have appreciably enhanced prescribing efficiency for proton pump inhibitors (PPIs) and statins in 2007 versus 2001. Statin utilization enhanced by measures to increase doses prescribed, including the Quality and Outcome Framework (QoF). Aims: Ascertain whether the plethora of measures continue to enhance prescribing efficiency for PPIs and statins. Second, assess whether the combined impact of the QoF targets and guidance enhances the prescribing of higher strength statins, mirroring the situation in England. Method: PPI and statin utilization measured in terms of defined daily doses (DDDs) and DDDs per 1000 inhabitants per day (2010 DDDs) between 2001 and 2010, number and strength of simvastatin and atorvastatin tablets dispensed, and reimbursed expenditure per DDD and 1000 inhabitants per year. Results: Expenditure per ODD for generic omeprazole in 2010 was 91{\%} below the 2001 originator price, leading to expenditure per 1000 inhabitants for PPIs in 2010 to be 56{\%} below 2001 despite a threefold increase in utilization. Expenditure per DDD for generic simvastatin in 2010 was 97{\%} below the 2002 originator price. Expenditure per 1000 inhabitants for statins in 2010 only increased by 7{\%} compared with 2001 despite a 6.2-fold increase in utilization. Utilization of higher strength statins has increased in recent years, with higher strength simvastatin (40 and 80 mg) accounting for 85{\%} of total statins (DDD basis) in 2010. Conclusion: Reforms appear to be working to further enhance prescribing efficiency. Utilization of higher strength statins in recent years should further improve outcomes",
author = "Marion Bennie and Brian Godman and Iain Bishop and Stephen Campbell",
year = "2012",
doi = "10.1586/erp.11.98",
language = "English",
volume = "12",
pages = "125--130",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. / Bennie, Marion; Godman, Brian; Bishop, Iain; Campbell, Stephen.

In: Expert Review of Pharmacoeconomics Outcomes Research, Vol. 12, No. 1, 2012, p. 125-130.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

AU - Bennie, Marion

AU - Godman, Brian

AU - Bishop, Iain

AU - Campbell, Stephen

PY - 2012

Y1 - 2012

N2 - Introduction: Multiple and intensive demand measures in Scotland have appreciably enhanced prescribing efficiency for proton pump inhibitors (PPIs) and statins in 2007 versus 2001. Statin utilization enhanced by measures to increase doses prescribed, including the Quality and Outcome Framework (QoF). Aims: Ascertain whether the plethora of measures continue to enhance prescribing efficiency for PPIs and statins. Second, assess whether the combined impact of the QoF targets and guidance enhances the prescribing of higher strength statins, mirroring the situation in England. Method: PPI and statin utilization measured in terms of defined daily doses (DDDs) and DDDs per 1000 inhabitants per day (2010 DDDs) between 2001 and 2010, number and strength of simvastatin and atorvastatin tablets dispensed, and reimbursed expenditure per DDD and 1000 inhabitants per year. Results: Expenditure per ODD for generic omeprazole in 2010 was 91% below the 2001 originator price, leading to expenditure per 1000 inhabitants for PPIs in 2010 to be 56% below 2001 despite a threefold increase in utilization. Expenditure per DDD for generic simvastatin in 2010 was 97% below the 2002 originator price. Expenditure per 1000 inhabitants for statins in 2010 only increased by 7% compared with 2001 despite a 6.2-fold increase in utilization. Utilization of higher strength statins has increased in recent years, with higher strength simvastatin (40 and 80 mg) accounting for 85% of total statins (DDD basis) in 2010. Conclusion: Reforms appear to be working to further enhance prescribing efficiency. Utilization of higher strength statins in recent years should further improve outcomes

AB - Introduction: Multiple and intensive demand measures in Scotland have appreciably enhanced prescribing efficiency for proton pump inhibitors (PPIs) and statins in 2007 versus 2001. Statin utilization enhanced by measures to increase doses prescribed, including the Quality and Outcome Framework (QoF). Aims: Ascertain whether the plethora of measures continue to enhance prescribing efficiency for PPIs and statins. Second, assess whether the combined impact of the QoF targets and guidance enhances the prescribing of higher strength statins, mirroring the situation in England. Method: PPI and statin utilization measured in terms of defined daily doses (DDDs) and DDDs per 1000 inhabitants per day (2010 DDDs) between 2001 and 2010, number and strength of simvastatin and atorvastatin tablets dispensed, and reimbursed expenditure per DDD and 1000 inhabitants per year. Results: Expenditure per ODD for generic omeprazole in 2010 was 91% below the 2001 originator price, leading to expenditure per 1000 inhabitants for PPIs in 2010 to be 56% below 2001 despite a threefold increase in utilization. Expenditure per DDD for generic simvastatin in 2010 was 97% below the 2002 originator price. Expenditure per 1000 inhabitants for statins in 2010 only increased by 7% compared with 2001 despite a 6.2-fold increase in utilization. Utilization of higher strength statins has increased in recent years, with higher strength simvastatin (40 and 80 mg) accounting for 85% of total statins (DDD basis) in 2010. Conclusion: Reforms appear to be working to further enhance prescribing efficiency. Utilization of higher strength statins in recent years should further improve outcomes

U2 - 10.1586/erp.11.98

DO - 10.1586/erp.11.98

M3 - Article

VL - 12

SP - 125

EP - 130

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -